Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 26 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 9574004

    Methods for treating or preventing asthma by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 21, 2017 · Expires Feb 16, 2037

    granted
  2. US 9554563

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted
  3. US 9556277

    Method of treating a TL1A-associated disease or disorder with human antibodies to TL1A

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted
  4. US 9550837

    Therapeutic uses of anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 24, 2017 · Expires Jan 19, 2037

    granted
  5. US 9545451

    Anti-PRLR antibodies and methods for killing PRLR-expressing cells

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 17, 2017 · Expires Jan 12, 2037

    granted
  6. US 9546218

    Anti-Tie2 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 17, 2017 · Expires Jan 12, 2037

    granted
  7. US 9540449

    Anti-PCSK9 antibodies with pH-dependent binding characteristics

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2017 · Expires Jan 5, 2037

    granted
  8. US 9532555

    Humanized dipeptidyl peptidase IV (DPP4) animals

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 3, 2017 · Expires Dec 29, 2036

    granted
  9. US 9533039

    Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 3, 2017 · Expires Dec 29, 2036

    granted
  10. US 9522185

    Human antibodies to GFR α3 and methods of treating pain associated with osteoarthritis or bone cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 20, 2016 · Expires Dec 15, 2036

    granted
  11. US 9511140

    Stable VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 6, 2016 · Expires Dec 1, 2036

    granted
  12. US 9497945

    Humanized dipeptidyl peptidase IV (DPP4) animals

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2016 · Expires Nov 17, 2036

    granted
  13. US 9498529

    Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2016 · Expires Nov 17, 2036

    granted
  14. US 9475875

    Anti-EGFRvIII antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  15. US 9475869

    Human antibodies to fel d1 and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  16. US 9462794

    Non-human animals having a humanized signal-regulatory protein gene

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 11, 2016 · Expires Oct 6, 2036

    granted
  17. US 9453072

    Anti-IL-33 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  18. US 9447173

    Human antibodies to respiratory syncytial virus F protein and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted
  19. US 9416167

    Stable liquid formulations of dimer VEGF antagonists

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 16, 2016 · Expires Aug 11, 2036

    granted
  20. US 9409990

    Methods of inhibiting tumor growth by antagonizing IL-6 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 9, 2016 · Expires Aug 4, 2036

    granted
  21. US 9402898

    Stabilized formulations containing anti-Ang2 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 2, 2016 · Expires Jul 28, 2036

    granted
  22. US 9399674

    Human antibodies to Clostridium difficile toxins

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 26, 2016 · Expires Jul 21, 2036

    granted
  23. US 9371383

    Anti-ASIC1 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 21, 2016 · Expires Jun 16, 2036

    granted
  24. US 9359437

    Antibodies comprising chimeric constant domains

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 7, 2016 · Expires Jun 2, 2036

    granted